We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,082

SEC settles with stock promoters in medical marijuana stock manipulation scheme
  • Katten Muchin Rosenman LLP
  • USA
  • July 17 2015

On July 9, the Securities and Exchange Commission settled with two stock promoters accused of reaping $2.5 million in illicit profits by manipulating

State AGs in the news
  • Dickstein Shapiro LLP
  • USA
  • May 15 2014

Bernard Nash and Milton A. Marquis Hot News Blog Post: Think You're Not a Holder of Unclaimed Property? Think Again! All 50 states have unclaimed

Online health care, consumer data, cybersecurity risks, accounting fraud, patents Expect Focus Vol. II, Spring 2015
  • Carlton Fields Jorden Burt
  • Global, USA
  • June 17 2015

Large-scale data breaches have become increasingly common, bringing with them not only bad press and loss of customer goodwill

First Circuit upholds dismissal of securities fraud action based upon immateriality of allegedly omitted information
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • July 27 2012

In In re Boston Scientific Corp. Securities Litigation, 2012 WL 2849660 (1st Cir. July 12, 2012), the United States Court of Appeals for the First Circuit affirmed the dismissal of a securities class action lawsuit against Boston Scientific Corporation (the “BSC”

Last man standing
  • Cooley LLP
  • USA
  • December 27 2013

The Gentiva securities class action is based on allegations that the company violated Medicare rules and artificially inflated the Medicare payments

SEC brings fraud case against biopharmaceutical company, three other companies and four executives for misleading investors about sole product and insider trading
  • Porter Wright Morris & Arthur LLP
  • USA
  • August 2 2011

On Monday, August 1, 2011, the SEC filed suit against eight defendants for making false statements in public filings regarding the status of the human clinical trials for the drug SF-1019 by Argyll Biotechnologies LLC

United States Supreme Court skeptical of requiring statistical significance as the test to determine materiality in securities fraud cases
  • Morrison & Foerster LLP
  • USA
  • January 11 2011

On Monday, January 10, 2011, the Supreme Court heard arguments in Matrixx Initiatives, Inc. v. Siracusano, No. 09-1156

U.S. Supreme Court Matrixx decision rejects statistical significance as bright-line test of materiality
  • Hogan Lovells
  • USA
  • April 11 2011

In its unanimous opinion in Matrixx Initiatives, Inc. v. Siracusano issued on March 22, the U.S. Supreme Court reaffirmed its long-established standard for determining materiality with respect to securities fraud claims under Section 10(b) of the Securities Exchange Act of 1934 and the SEC's Rule 10b-5

French doctor charged in criminal and civil insider trading cases
  • Porter Wright Morris & Arthur LLP
  • USA
  • November 3 2010

The criminalization of securities enforcement has increased in recent years

Pharmaceutical and other companies beware: new Supreme Court decision weighs in on adverse event reports and potential liability under federal securities laws
  • Squire Patton Boggs
  • USA
  • March 23 2011

In 2010 the US Supreme Court agreed to hear another securities fraud case Matrixx Initiatives, Inc. v. Siracusano which could significantly increase pharmaceutical and other companies’ exposure under federal securities laws, especially those companies that make disclosure decisions based on the statistical significance of certain events